Dr. Dirk Bernhardt

Counselling of 4 different SMEs from abroad approaching the DACH markets: Determined market potential based on incidence by ICD-10 and OPS; Assessed competitive market as to inform USP and the value added of the innovation; Initiated KOL mapping and subsequent customer acquisition activities; Provided guidance regarding reimbursement by the German SHI; Compiled dossier including recommendations for launch and product roll out

1. Determined product strategy including HTA-value story and positioning for two rare disease conditions such as inoperable Head and Neck cancer and Sarcoma, based on: o primary market research with providers and advisory board guidance o systematic literature review and retrospective clinical data in EU5 countries 2. Provided framework for marketing planning based on EU5 market analysis by provider distribution and revenue potential

Coordination, implementation of M&S activities to achieve commercial turn-around of Foscan®-based photodynamic therapy for rare Cholangiocarcinoma and Head and Neck cancer: Increased sales by 15% over last year; Accomplished filing of applications for reimbursement by the German statutory health insure (NUB application), benefit assessment and prolongation of product registration in France and Belgium; Established sustainable medical liaison with European decision makers in the relevant disease area

Supervised authoring of medical background information of the Wilex product portfolio, i.e. product monograph, promotional material; Implementation of awareness campaigns for the Wilex product portfolio in the context of personalized medicine in urologic-oncology, pancreatic and breast cancer; Provided marketing plan and related activities for EU5 launch of Rencarex®; In addition the role included alliance management of Wilex licencees, business development and due diligence support

Introduced principles of portfolio management for evaluation of new product candidates, managed interface with pharmaceutical-, process-, and regulatory development Supervised a team of 5 members to manage worldwide marketing services for sales force, including definition of USP of branded generics and decrease of go-to-market time Supervised timely launch of two generic products prior to the originator’s patent expiration

Initiated market research studies for product branding and determination of brand end user prices Internal counsel for product managers to prepare for and conduct three launches in highly competitive markets of antithrombotic therapy, osteoporosis, and break-through pain treatment Nycomed project team leader for the integration of sales forces during merger with Altana AG

Mikrobiologie; Biochemie; Immunologie